Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/13—Coniferophyta (gymnosperms)
  • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
  • A61K36/235—Foeniculum (fennel)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
  • A61K36/286—Carthamus (distaff thistle)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/55—Linaceae (Flax family), e.g. Linum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/82—Theaceae (Tea family), e.g. camellia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders

Definitions

• the invention relates to new uses of vegetable oils and their components.
• Saturated and unsaturated fatty acids are contained in the cell membrane of cells.
• the concentration of unsaturated fatty acids plays a role in the barrier properties of the skin as well as in the reactivity of cells in inflammatory and immunological processes such as z. B. in psoriasis or atopic dermatitis.
• the current state of therapy for skin diseases has disadvantages.
• Systemic therapy is only possible with strong side effects, e.g. B. in the treatment with cyclosporin (kidney-toxic, immunosuppressive), retinoids (teratogenic, blood pressure and serum lipid value increasing), methotrexate (hepatotoxic), UV therapy (PUVA, UV-B, carcinogen). Therefore long-term therapy is not possible. After stopping, the symptoms return immediately. Interval therapy (between the episodes of the disease) and prophylaxis are also not possible because of the side effects. The same applies to other inflammatory dermatoses, such as. B. Atopic dermatitis (glucocorticoid therapy).
• Topical therapy is only possible in the case of small-scale infestation in areas of the body that are accessible to the patient. Complicated to use is e.g. B. the dithranol therapy. It cannot be used on hard-to-reach areas such as the back, mucous membranes or hairy head.
• mainly external therapeutic agents for eczema treatment containing coconut oil and palm kernel oil are known, which are characterized by a high content of lauric acid and myristic acid. They have not always proven to be beneficial.
• the object of the invention is, in particular, to enable effective prophylaxis, interval and long-term therapy without any particular side effects, which is also suitable without problems for particularly needy patients, such as children or the elderly. It should also be easy to use.
• the invention relates to the use of
• trace elements e) minerals, f) vitamins, g) amino acids, h) anti-inflammatory and / or immunosuppressive substances i) antipsoriatics, j) keratolytics and / or k) urea, for the treatment and prophylaxis of inflammatory or immunological diseases, diabetes, alcoholism and wounds.
• One or more components from each of only one of groups d) to k) are preferably used.
• Vegetable oils and fats with a high content of oleic acid and / or linoleic acid are preferably used. This applies to the case that they are used according to I. a) alone or in a mixture with components a), but also for combinations with the other active ingredients.
• Suitable oils are e.g. B. castor oil, sunflower oil, rapeseed oil, sesame oil, linseed oil, safflower oil, cottonseed oil, palm oil, palm kernel oil, olive oil, babassufett, corn oil, wheat germ oil, pumpkin seed oil, rice germ oil, rape oil, coconut oil, tall oil, cocoa butter, shea butter, borne tallow.
• Sunflower oil soybean oil, peanut oil, rapeseed oil, sesame oil, safflower oil, tall oil, linseed oil, rapeseed oil, mustard oil, olive oil, tea seed oil, coriander oil, safflower oil, safflower oil, borage oil, evening primrose oil, fennel oil, and blackberry seed oil.
• Olive oil corn oil, peanut oil, soybean oil, sunflower oil and wheat germ oil are particularly preferred.
• Olive oil sunflower oil, corn oil, wheat germ oil or tea seed oil are particularly preferred.
• oils and fats can be used alone or as mixtures and are particularly suitable for the prophylaxis and treatment of psoriasis or atopy.
• olive oil can be used as an active ingredient just like the other active ingredients according to the invention for the treatment of the diseases or conditions mentioned according to the invention, in particular psoriasis.
• Olive oil, oleic acid and / or linoleic acid or their derivatives are particularly preferably used, in particular also when two or more components a) are used or when combinations with other active compounds according to the invention are used.
• Animal fats or animal oils which may be used are tallow or lard, for example beef tallow, milk fat, mutton tallow, hoof oil, pork lard, goose lard, marine oils such as whale oil, sperm oil, seal oils, herring oils such as e.g. B. mackerel oil, pilchard oil, menhaden oil. Fish oils are preferred.
• fatty acids of the n-3 series or their derivatives z are optionally used fatty acids of the n-3 series or their derivatives z.
• B alpha-linolenic acid or its metabolites or their derivatives, especially the acids 18: 4n-3, 20: 4n-3, 20: 5n-3, 22: 5n-3, 22: 6n-3.
• Eicosapentaenoic acid (EPA), docosatetraenoic acid, docosapentaenoic acid and docosahexaenoic acid and their derivatives are particularly preferred.
• EPA and its derivatives are particularly preferred.
• n-6 fatty acids are gammalinolenic acid (GLA), dihomogammalinolenic acid (DGLA) and arachidonic acid (AA).
• GLA gammalinolenic acid
• DGLA dihomogammalinolenic acid
• AA arachidonic acid
• the acids of the invention can be administered in the form of the acid itself or as a derivative, e.g. B. ester, amide, salt or any other functional derivative which is capable of being converted into a biologically active form of the acid in the body and which can come from natural or synthetic sources.
• a derivative e.g. B. ester, amide, salt or any other functional derivative which is capable of being converted into a biologically active form of the acid in the body and which can come from natural or synthetic sources.
• Suitable physiologically functional derivatives according to the invention which are converted to acids in the body and follow the known metabolic pathway, are, for. B. physiologically acceptable salts, esters, especially glycerides and alkyl esters (z. B. C-
• esters especially glycerides and alkyl esters
• amides z. B. C ⁇ -C ⁇ mono- or dialkylamides
• phospholipids phospholipids
• Olive oil combined with fatty acids of the n-3 and / or n-6 series, in particular EPA and / or GLA or their derivatives in each case,
• Oleic acid combined with fatty acids of the n-3 and / or n-6 series, in particular EPA and / or GLA or their derivatives,
• - Linoleic acid combined with fatty acids of the n-3 and / or n-6 series, in particular EPA and / or GLA or their derivatives.
• Corn oil, peanut oil, soybean oil, sunflower oil, wheat germ oil or tea seed oil can also be used advantageously instead of olive oil.
• the weight percentages given below are also preferred for these combinations.
• the combinations of the fatty acids of the n-3 and n-6 series are also advantageously used in the form of natural fats and oils in which they are present, for example fish oils, borage oil, evening primrose oil or currant seed oil.
• Combinations of olive oil and / or oleic acid and / or linoleic acid are also preferably used, in particular also in the above combinations.
• Preferred trace elements that may be used in combination are:
• Iron is preferred. It can be used in a known manner as a salt or iron complex, preferably in amounts which allow the known daily doses of 1 to 100 mg, preferably 5-30 mg per day (calculated as iron) to be achieved.
• Selenium in the form of known selenium compounds, e.g. B: in usual daily doses of 0.05-0.1 mg (based on selenium), in deficiency conditions also up to 0.6 mg.
• Preferred minerals, sodium, potassium and / or calcium compounds used in combination in particular in the form of their phosphates or chlorides.
• Calcium chloride is particularly preferred.
• Preferred vitamins that are optionally used in combination are:
• Nicotinamide (niacin)
• vitamin C Ascorbic acid (vitamin C).
• Vitamin A Vitamin A acid, retinol, retinol acetate, vitamin E, tocopherol acetate, vitamin D, e.g. B. D--, D 2 , D 3 , and / or vitamin C.
• Preferred amino acids which are optionally used in combination are those amino acids which are contained in collagen, elastin, glycosaminoglycans or hyaluronic acid, in particular arginine, proline, hydroxyproline, alanine, valine, cystine, glycine, lysine and hydroxylysine.
• Preferred anti-inflammatory and / or immunosuppressive substances that are optionally used in combination are corticosteroids (eg: prednisolone, triamcinolone), methotrexate and cyclosporin.
• combination antipsoriatics eg. B. dithranol, fumaric acid, for example as disodium salt or ethyl hydrogen fumarate and 8-methoxypsoralen.
• Salicylic acid is preferred as the keratolytic agent optionally used in combination.
• antipsoriatics, keratolytics and urea are particularly preferably administered externally, especially in topical preparations.
• Antipsoriatics can be contained in amounts of 0.1-5% by weight, preferably 2-4% by weight, in each case based on the entire preparation.
• Keratolytics can be contained in amounts of 1-5% by weight, preferably 2-4% by weight, based in each case on the entire preparation.
• Urea can be present in amounts of 0.01-30% by weight, preferably 0.1-12% by weight, based in each case on the entire preparation.
• the inflammatory and immunological diseases according to the invention are in particular inflammatory or immunologically / allergically caused diseases of the skin, the appendages of the skin, the mucous membranes, the intestine, the cartilage, the diseases associated with the atopic form, and acute and chronic wounds, alcoholism and diabetes.
• the active compounds according to the invention are particularly suitable for the prophylaxis and treatment of diseases in accordance with the assignment and description of the standard work O. Braun-Falco, G. Plewig, H. H. Wolff, R. K. Winkelmann, Dermatology, Springer Verlag 1984, preferably as on pages XV-XXV
• SPARE BLADE specified, in particular dermatitis (e.g. contact dermatitis) and eczema (e.g.: atopic dermatitis), drug reactions, urticaria diseases, physically and chemically related skin disorders (e.g. sunburn), erythematous, erythematosquamous and papular skin disorders (e.g. Psoriasis), blistering diseases (e.g. pemphigus), sterile pustular diseases, inflammatory or immunologically related keratoses (e.g. ichthyoses, winter xerosis), inflammatory or immunological disorders of the connective tissue (e.g.
• scleroderma lupus
• des Cartilage e.g., scleroderma, lupus
• neurological or psychogenic skin diseases e.g. pruritus
• inflammatory diseases of the sebaceous follicles e.g. acne
• mucous membranes of non-bacterial origin e.g. balanitis, vulvovaginitis,
• the active ingredients are administered in order to reduce the frequency and severity of manifestations of the diseases.
• Treatment in the manifest stage leads to its shortening and alleviation of the symptoms.
• are preferred -C2 mono- or dialkylamides or water-soluble salts of the acids according to the invention, in particular the alkali metal salts, e.g. B: the sodium salt or the potassium salt and also the ammonium salt.
• Di- and triglycerides are particularly preferred in the treatment of disturbed keratinization and psoriasis or atopy.
• the active ingredients are surprisingly suitable for curing the conditions mentioned, in particular for long-term therapy, interval therapy and prophylaxis.
• One of the components of a) is preferably used alone or as a mixture of two or more of the components of a).
• the active substances from a) can also be used together with substances from b) and / or c). These combinations preferably contain high proportions by weight of one or more components of a), preferably a predominant proportion by weight of a). Combinations are preferred which contain a) in amounts of 50-99% by weight, in particular 60-90% by weight or also 70-85% by weight, based in each case on combinations of a), b) and c ), where b) and / or c) are present in amounts which correspond to the addition to 100%. If appropriate, components b) and / or c) are each preferably present in amounts of 1-25% by weight. Combinations of substances a) and c) are preferred, in particular also in the amounts specified above.
• active ingredients according to I. a) -c) are combined with components according to II. D) -k).
• the components d) -k) are preferably selected in such amounts that the daily doses for oral administration are those as described in the literature and e.g. B. are recommended as a daily requirement for humans. This simple quantity adjustment is readily possible for the person skilled in the art. Well-suited values are e.g. B. in
• Suitable daily doses for trace elements are e.g. B .:
• a combination of 10 g (daily dose) as stated above, but which contains minerals, can e.g. B. 1-20 wt .-% CaCl 2 , preferably 5-15 wt .-%.
• B. 1-20 wt .-% CaCl 2 preferably 5-15 wt .-%.
• lipophilic substances which on the one hand are more easily absorbed and on the other hand are stored in the body's own fatty tissue, must be more limited in their daily dose than hydrophilic substances which can easily be excreted in the event of an overdose.
• vitamin E For oral administration of 10 g of the combination of I. a) with 2) vitamin E, 1-6% by weight of vitamin E is preferably combined with 94-99% by weight of the components described under I. a).
• the 5-10 times the amount of the orally used doses of and I. a) and 1) and 2) components are incorporated as a daily dose in the corresponding formulations, as explained below.
• Topical preparations containing vitamins and / or trace elements and / or minerals are preferred.
• Vitamins D, its derivatives or vitamin A or its derivatives are preferably present in the topical preparations in amounts of 0.001-0.1% by weight, particularly preferably 0.005-0.05% by weight.
• Amounts are preferably selected which are about five to ten times the specified or known, for. B. Average daily oral doses. Accordingly, taking into account the daily application quantities, the weight percentages of these substances are in the topical ones
• compositions which contain the compounds according to the invention or their pharmaceutically acceptable derivatives together with a pharmaceutically acceptable diluent or carrier.
• the compounds of the present invention can be administered orally or parenterally or rectally, e.g. B. in a dosage of 10 mg to 800 g, preferably 1 g to 100 g, particularly preferably 2 g to 10 g per day, in particular also in divided doses, for example twice to four times a day.
• the compounds according to the invention and the combinations according to the invention can also be easily incorporated into conventional pharmaceutical and cosmetic bases for topical applications, and the corresponding topical pharmaceutical and cosmetic preparations or agents are thus obtained.
• They are preferred in amounts of 0.1 to 99.5% by weight, preferably also in amounts of 1 to 50% by weight, in particular in amounts of 2 to 30% by weight, in each case based on the total weight of the topical agent.
• the preparations can be used several times a day in the usual way.
• the invention also relates to the use of the active compounds according to the invention for producing pharmaceutical agents, topical pharmaceutical and cosmetic agents for the prophylaxis and treatment of the conditions according to the invention.
• the invention also relates to the use of pharmaceutical agents and topical pharmaceutical and cosmetic agents containing active ingredients according to the invention for the prophylaxis and treatment of the above conditions.
• the active ingredients are surprisingly suitable for curing the conditions mentioned, in particular for long-term therapy, interval therapy and prophylaxis.
• Treatment of psoriasis and atopic dermatitis is particularly preferred.
• the active compounds according to the invention can be mixed with customary pharmaceutically acceptable diluents or carriers and, if appropriate, with other auxiliaries and administered, for example, orally or parenterally or rectally.
• You can preferably take orally in the form of powder, granules, capsules, pills, tablets, film-coated tablets, dragees, syrups, emulsions, suspensions, dispersions, aerosols and solutions as well as liquids, or as suppositories, vaginal balls or parenterally, e.g. B. in the form of liquids and solutions, emulsions or suspensions, for example as infusion solutions.
• Oral preparations can contain one or more additives such as sweeteners, flavoring agents, colorants and preservatives.
• Tablets can contain the active ingredient mixed with customary pharmaceutically acceptable auxiliaries, for example inert diluents such as calcium carbonate, sodium carbonate, lactose and talc, granulating agents and agents which promote the disintegration of the tablets when administered orally, such as starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate, stearic acid and talc.
• auxiliaries for example inert diluents such as calcium carbonate, sodium carbonate, lactose and talc, granulating agents and agents which promote the disintegration of the tablets when administered orally, such as starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate, stearic acid and talc.
• Suitable carriers are, for example, milk sugar (lactose), gelatin, corn starch, stearic acid, ethanol, propylene glycol, ether of tetrahydrofurfuryl alcohol and water.
• the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, z. B. in the case of the use of water as a diluent, organic solvents can optionally be used as auxiliary solvents.
• tablets can of course also contain additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatin and the like, in addition to the carrier substances mentioned.
• Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting.
• the active compounds can be used in the case of aqueous suspensions and / or elixirs which are intended for oral use.
• solutions of the active ingredients can be used using suitable liquid carrier materials.
• Capsules can contain the active ingredient as a single ingredient or mixed with a solid diluent such as calcium carbonate, calcium phosphate or kaolin.
• a solid diluent such as calcium carbonate, calcium phosphate or kaolin.
• the injectable preparations are also formulated in a manner known per se (ampoules, bottles).
• the pharmaceutical preparations can contain the active ingredient in an amount of 0.1 to 90 percent by weight, in particular 1-90 percent by weight. Capsules are particularly preferred. Individual doses contain the active substances preferably in an amount of 100 to 600 mg.
• salts are sparingly soluble in water, they can be administered in the form of slurries.
• the sodium and potassium salts have a particularly good solubility in water.
• salts are preferably injected intravenously or intramuscularly in the form of an aqueous solution such as physiological saline.
• the topical compositions according to the invention can be formulated as liquid, pasty or solid preparations, for example as aqueous or alcoholic solutions, aqueous suspensions, emulsions, ointments, creams, oils, powders, powders or sticks.
• the active ingredients can be incorporated into pharmaceutical and cosmetic foundations for topical applications which, as further components, include, for example, oil components, fat and waxes, emulsifiers, anionic, cationic, ampholytic, zwitterionic and / or nonionic surfactants, and lower polyhydric alcohols, water, preservatives, buffers, thickeners, fragrances, dyes and opacifiers.
• Emulsions e.g. B. W / O emulsions using oils and fats per se or ointments.
• antioxidants to the active ingredients and the preparations, the pharmaceutical and topical agents.
• the use of natural or nature-identical compounds is particularly preferred.
• SPARE BLADE such as tocopherols.
• the antioxidants mentioned are in the agents according to the invention, for. B. in amounts of 0.01 - 5 wt .-%, in particular from 0.5 - 2 wt .-%, based on the total agent. They serve to stabilize the active ingredient.
• the invention is primarily seen in the use of pharmaceutical or cosmetic compositions, but it is also possible to incorporate the active ingredients in dietary additives, in dietary margarine or other foods.
• dietary or pharmaceutical compositions are within the scope of the invention.
• Psoriasis Area and Severity Index is a measure for the quantification of psoriasis symptoms according to Fredriksson and Pettersson (1978).
• Possible interferences such as B. other organ findings, abnormal serum values, other psoriasis therapy, climatic influences.
• the clinical condition was improved by at least 43%.
• any dosage unit should not exceed the amount appropriate for the rate and type of application to be carried out, but on the other hand it is also desirable to that the desired rate of application is achieved through a lower number of doses.
• the rate of administration will mostly depend on the precise pharmacological action that is desired.
• One capsule containing olive oil was administered in 0.5 g capsules six times a day for the conditions listed above.
• a capsule containing 70% olive oil and 30% salmon oil was administered in 0.5 g capsules eight times a day for the conditions as described above.
• a capsule containing 50 mg linoleic acid, 20 mg 22: 4n-6, 20 mg 22: 5n-6, 10 mg 20: 5n-3, 20 mg 22: 5n-3 and 20 mg 22: 6n-3 was used four times taken a day for the conditions as described above.
• the water which has been heated to the same temperature, is incorporated into the mixture of wax, walrus and olive oil, which has been heated to about 60 ° C. and to which a suitable antioxidant can be added.
• the ointment is stirred until it cools.
• This ointment was applied to the affected skin areas at least twice a day as described above.
• the mixture of propylene glycol + water heated to 80 C is added in portions and with constant stirring to the mixture of hardened olive oil + cetylan heated to 80 C; then it is stirred cold and the evaporated water is replaced.
• Oleic acid sodium salt 5 optionally colorants, fragrances
• the production takes place in a manner known per se.
• the fat phase and the water phase are prepared separately by mixing the constituents, possibly with little heating. Then the phases are mixed and emulsified.
• the cream was applied to the affected skin areas at least twice a day as described above.
• the wool wax alcohol ointment and the olive oil are 75 -
• a capsule with the following contents was administered orally twelve times a day for the conditions mentioned:
• a capsule with the following contents was administered twelve times a day for the conditions mentioned:
• Example 16 A cream as described in Example 16 was prepared in a known manner, but urea was used instead of arginine hydrochloride.

Landscapes

• Health & Medical Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Alternative & Traditional Medicine (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Botany (AREA)
• Biotechnology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Nutrition Science (AREA)
• Biomedical Technology (AREA)
• Addiction (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Immunology (AREA)
• Dermatology (AREA)
• Psychiatry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=6497332

Family Applications (1)

Country Status (5)

Families Citing this family (13)

Family Cites Families (31)

• 1993
  • 1993-09-10 DE DE4330664A patent/DE4330664A1/de not_active Withdrawn
• 1994
  • 1994-09-09 EP EP94926929A patent/EP0720481A1/de not_active Withdrawn
  • 1994-09-09 AU AU76570/94A patent/AU7657094A/en not_active Abandoned
  • 1994-09-09 JP JP7508466A patent/JPH09502196A/ja active Pending
  • 1994-09-09 WO PCT/EP1994/003020 patent/WO1995007091A1/de not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events